Evaluation of CS1, a novel anti-thrombotic drug, in man and animal
|Coordinator||CERENO SCIENTIFIC AB - Cereno Scientific AB, Mölndal|
|Funding from Vinnova||SEK 700 000|
|Project duration||June 2017 - December 2018|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
|Call||SWElife and Medtech4Health- Project proposals to improve health 2017|
Purpose and goal
The long-term aim for Cereno Scientific AB is to develop a novel antithrombotic drug with adequate effectiveness and lower risk of severe bleedings than available therapy, thus providing an additional treatment option to current therapies with a profile offering effective and safe prevention of blood clot related diseases such as VTE, myocardial infarction and stroke.
Expected results and effects
Cereno Scientific’s unique drug candidate CS1 strengthens the body’s own blood clotting defense through targeting the endogenous fibrinolytic system and in this way prevents thromboembolic events. The Swelife/MedTech4Health grant have contributed in evaluation of the effects of CS1. A predefined goal was that after completion of the Swelife/MedTech4Health project, Cereno Scientific should plan for and initiate a phase II study. Cereno Scientific has signed a contract with OCT, a Russian CRO, to conduct a phase II study in patients undergoing orthopedic surgery.
Planned approach and implementation
A phase 1 study with CS1 was performed during Q4 2017-Q1 2018. The study was performed by Clinical Trial Consultants (CTC) AB in Uppsala, Sweden. This was the first time CS1 was evaluated in man. 13 healthy slightly obese volunteers were included and treated with CS1 once daily for 28 consecutive days. The study demonstrated the expected properties of CS1 in man with positive results regarding safety and its effect on hemostatic biomarkers.